The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 601–700 of 958
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
“…systemically administered, fluorescently labeled liraglutide and semaglutide gain access to the median eminence and ARC and to a lesser extent the PVH and DMH [51, 126], while administration of liraglutide into the ARC, PVH, and LHA (but not the DMH and VMH) robustly reduces food intake [120, 127].”
InfluentialGolden, A. K., & Davis, J. M. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s509971 · Cited by 11
“107,110 120 Sympathomimetic medications have been associated with side effects such as increased blood pressure and insomnia.”
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“This dual action enhances satiety and reduces hunger, contributing significantly to the anti-obesity effects of GLP-1Ras [ 26, 27 ].”
GLP-1 agonists: a game changer in pain treatment and addiction
Bade, S., Hurdle, M. F. B., Bade, S., Encalada, S., Kanahan-Osman, S., & Gupta, S. (2025) · Pain Management · doi:10.1080/17581869.2025.2536998 · Cited by 12
Trapp, S., & Skoug, C. (2025) · Endocrinology · doi:10.1210/endocr/bqaf169 · Cited by 12
“Peripherally administered GLP-1RAs reduce food intake by engaging central nervous pathways (85-87), though most likely not via GLP1-Rs located inside the BBB (88).”
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
Guo, J. S., Hayes, M. R., Leggio, L., Oru, E., & Rinaman, L. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1375-25.2025 · Cited by 13
In vivo transcriptomic, functional, circuit-based, and translational analyses of enteric neurons
Millett, C. J., Shaver, J. J., Bracken, B., Jones, S. J., Lovelett, R. J., Rubinow, D. A., Singhal, R., Charlton, C., Piazza, N., Hauck, Q., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.024 · Cited by 13
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 13
“10 Here, we provide some preclinical data on how GLP-1 medicines interact with and ameliorate CNS pathology, while summarizing the clinical data interrogating the actions of GLP-1 medicines in neurodegenerative disorders, substance use disorders (SUDs), psychiatric disorders, headache, stroke, and…”
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 17
Welling, M. S., Mohseni, M., van der Valk, E. S., van Hagen, J. M., Burgerhart, J. S., van Haelst, M. M., & van Rossum, E. F. C. (2023) · iScience · doi:10.1016/j.isci.2023.106199 · Cited by 11
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
Pati, B., Sendh, S., Sahu, B., Pani, S., Jena, N., & Bal, N. C. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00107e · Cited by 10
Clinical and Therapeutic Implications of Male Obesity
Lenart-Lipińska, M., Łuniewski, M., Szydełko, J., & Matyjaszek‐Matuszek, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165354 · Cited by 15
“This mechanism is based on the stimulation of transcriptional neurons regulated by POMC and CART (cocaine and amphetamine related peptide), which suppress appetite and indirectly inhibit the protein neurons associated with the NPY (neuropeptide Y) and AgRP (agouti-related protein), neuropeptides responsible for the fe…”
BackgroundRuska, Y., Peterfi, Z., Szilvásy‐Szabó, A., Kővári, D., Hrabovszky, E., Dorogházi, B., Gereben, B., Tóth, B., Matziari, M., Wittmann, G., et al. (2023) · Thyroid · doi:10.1089/thy.2023.0284 · Cited by 17
“18 However, we recently showed that a population of NPY neurons express GLP-1R, 21 indicating that GLP-1R agonists may have direct effects on these neurons.”
InfluentialDumiaty, Y., Underwood, B. M., Phy‐Lim, J., & Chee, M. J. S. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102427 · Cited by 13
“The PVN was another hypothalamic region implicated in the anorectic effects of GLP-1 action (Secher et al., 2014), but the anorectic Y. Dumiaty et al. effects of peripherally administered liraglutide persisted despite the blockade of GLP-1R or when the PVN region was lesioned (Secher et al., 2014).”
BackgroundDocherty, N. G., & le Roux, C. W. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.012 · Cited by 11
“The weight-reducing effects of liraglutide are mediated via direct pharmacological stimulation of hypothalamic POMC neurones [31].”
BackgroundKohno, D., Furusawa, K., & Kitamura, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0389 · Cited by 8
“This is simi‐ lar to obscure alteration of Npy, Agrp, and Pomc mRNA expression levels after administration of liraglutide [15].”
BackgroundL’obésité chez l’adulte : ligne directrice de pratique clinique
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L. D., Campbell-Scherer, D. L., Adamo, K. B., Alberga, A. S., Bell, R. C., Boulé, N. G., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707-f · Cited by 31
Rakhat, Y., Wang, L., Kaneko, K., Han, W., Seino, Y., Yabe, D., & Yada, T. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.027 · Cited by 11
Colin, I. M., Colin, H., Dufour, I., Gielen, C.-E., Many, M., Saey, J.-P., Knoops, B., & Gérard, A.-C. (2016) · Physiological Reports · doi:10.14814/phy2.12886 · Cited by 8
“15 | e12886 Page 1 body weight, and regulation of immune functions (Campbell and Drucker 2013; Baggio and Drucker 2014; Secher et al. 2014; Sisley et al. 2014; Drucker 2015).”
BackgroundRebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Singh, K., Aulakh, S. K., Nijjar, G. S., Singh, S., Sandhu, A. P. S., Luthra, S., Tanvir, F., Kaur, Y., Singla, A., & Kaur, M. S. (2024) · Cureus · doi:10.7759/cureus.64738 · Cited by 20
Hunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment
Cao, Y., & Tong, Q. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100569 · Cited by 10
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
“NPY/AgRP neurons stimulate the hunger center via ghrelin, a peptide secreted from the stomach, and inhibit the satiety center, resulting in increased appetite by blocking POMC/CART neurons and melanocortin receptors 3 and 4 (MC3/4R) [7–9].”
Obesity: assessment and treatment across the care continuum
Kushner, R. F., & Marla Shapiro, C. M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2521433 · Cited by 14
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 11
Wang, D., Wang, J., Li, B., Yang, S., Guo, F., Zheng, B., & Wang, J. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01312-4 · Cited by 10
“Unlike GLP-1 analogs such as liraglutide and semaglutide, which show limited BBB penetration (Kp, brain ~ 0.02–0.05) (Rhea et al. 2024; Lee et al. 2023; Hunter and Hölscher 2012; Secher et al. 2014), TZP’s dual agonism and fatty acid modification may enhance its BBB permeability.”
InfluentialLoeffler, M., Klepac, K., Baljuls, A., Hamilton, B. S., Mayer‐Wrangowski, S. C., Haebel, P., & Zimmermann, T. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101765 · Cited by 8
“the CNS, as demonstrated for the lipidated GLP-1 analogs liraglutide and semaglutide [30,31].”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 10
Mallah, M. A., Soomro, T., Noreen, S., Ali, M., Kafle, A., Khatoon, N., & Naveed, M. (2023) · International Journal of Rehabilitation Research · doi:10.1097/mrr.0000000000000565 · Cited by 8
Boutari, C., Pοlyzos, S. A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.007 · Cited by 8
Babic, I., Sellers, D., Else, P. L., Nealon, J. R., Osborne, A. L., Pai, N. B., & Weston–Green, K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981377 · Cited by 11
“Evidence suggests that liraglutide-induced weight loss is mediated by the activation of GLP-1Rs in the hypothalamus and the DVC, as GLP-1R neurotransmission directly stimulates POMC neurons and indirectly inhibits NPY neuronal signalling via GABA-dependent inhibition (Secher et al., 2014).”
BackgroundDischinger, U., Heckel, T., Bischler, T., Hasinger, J., Königsrainer, M., Schmitt-Böhrer, A. G., Otto, C., Faßnacht, M., Seyfried, F., & Hankir, M. K. (2021) · Nutrients · doi:10.3390/nu14010116 · Cited by 10
“In this brain region, the expression of key orexigenic neuropeptides such as neuropeptide Y (NPY) and agoutirelated peptide (AgRP) and anorexigenic neuropeptides such as proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) is affected by caloric restriction [49,50], RYGB [49,51], and lir…”
BackgroundSong, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 10
“Studies in obese mouse models have shown that GLP-1RAs can bind to GLP1 receptors in specific brain regions related to appetite regulation, leading to the stimulation of proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons, inhibition of neuropeptide Y, increased satiety, reduced hun…”
Tolerance Does Not Develop Toward Liraglutide’s Glucose-Lowering Effect
Sedman, T., Vasar, E., & Volke, V. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00199 · Cited by 9
“The appetite-suppre ssing and weight-reducing effects of GLP-1 analogues are a combination of GLP-1 receptor effects on the vagus nerve and in the area postrema, as well as in the underlying nuc leus of the solitary tract [6] and A D V A N C E A R T IC LE : T H E J O U R N A L O F C LI N IC A L”
BackgroundAfferent Endocrine Control of Eating
Langhans, W., & Holst, J. J. (2016) · Wiley eBooks · doi:10.1002/9781118839317.ch2 · Cited by 8
Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamusPreprint
Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S. H., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557967 · Cited by 8
Self-citationA Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsPreprint
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A. K., Li, O. D.-A., Ogilvie, S., Keeler, A. B., Tian, G., Koita, O., Shi, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628169 · Cited by 8
Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 8
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“POMC neurons promote satiety, while AgRP neurons promote hunger [28].”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Sayers, S., & Wagner, E. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083897 · Cited by 9
“In accordance with this finding, others have shown that the GLP1-induced inhibition of ARC NPY/AgRP neurons is due, in part, to enhanced GABA A receptor-mediated input onto these cells [10,20].”
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Hypothalamic GPCR Signaling Pathways in Cardiometabolic Control
Deng, Y., Deng, G., Grobe, J. L., & Cui, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.691226 · Cited by 8
As, A., Шохин, И. Е., Rogozhina, E. A., Геннадьевна, Б. Т., Nevretdinova, M. E., Bely, P. A., Zaslavskaya, K. Y., Куркин, Д. В., Koryanova, K. N., Mishchenko, E. S., et al. (2023) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-3-255-276 · Cited by 9
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists
Cook, T. M., Fuller, K. N. Z., & Sandoval, D. A. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110269 · Cited by 7
Vana, V., Lærke, M. K., Kleberg, K., Mroz, P. A., Lindberg, B. L., Ekberg, J. H., Rehfeld, J. F., Schwartz, T. W., & Hansen, H. S. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113315 · Cited by 7
Klemettilä, J.-P., Solismaa, A., Seppälä, N., Hämäläinen, M., Moilanen, E., Leinonen, E. V. J., & Kampman, O. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114227 · Cited by 8
“Arcuate nucleus of the hypothalamus is a main site mediating the anorectic action of GLP-1 receptor (Secher et al., 2014).”
Xie, Y., Cheng, D., Wang, L., Chen, F., Chen, H., Ma, H., Yang, Y., & Yuan, X. (2022) · Aquaculture Reports · doi:10.1016/j.aqrep.2022.101045 · Cited by 7
Perens, J., & Hecksher‐Sørensen, J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.866884 · Cited by 8
Self-citationWang, Y., Wu, Y., Wang, A., Wang, A., Alkhalidy, H., Helm, R. F., Zhang, S., Ma, H., Zhang, Y., Gilbert, E. R., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1051452 · Cited by 11
Griffin, H., Sullivan, S. C., Barger, S. W., Phelan, K. D., & Baldini, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010629 · Cited by 7
“Consistent with that, it has been reported that GLP1R expressed in neurons mediates liraglutide’s ability to decrease body weight in mice with DIO [58] and that GLP1 directly stimulates POMC neurons in the arcuate nucleus to decrease body weight [59].”
BackgroundWilbs, J., Raavé, R., Boswinkel, M., Glendorf, T., Rodriguez, D. J., Fernandes, E. F. A., Heskamp, S., Bjørnsdottir, I., & Gustafsson, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02073 · Cited by 7
Mattar, P., Jaque, C., Teske, J. A., Morselli, E., Kerr, B., Cortés, V., Baudrand, R., & Perez‐Leighton, C. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1164047 · Cited by 7
“However, whether tanycytes mediate EX4 transport into the brain has not been examined (46).”
BackgroundMcEwen, H. J. L., Cognard, E., Ladyman, S. R., Aung, Z. K., Tups, A., Shepherd, P. R., & Grattan, D. R. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12607 · Cited by 7
Milonas, D., Didangelos, T., Hatzitolios, A. I., & Τζιόμαλος, Κ. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0580-z · Cited by 8
The metabolic actions of neurotensin secreted from the gut
Ratner, C., Hundahl, C., & Holst, B. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000085 · Cited by 7
Sex differences in GLP-1 signaling across speciesPreprint
Roseberry, T., Grossrubatscher, I., Krausz, T., Wang, Y.-J., Schwartz, M. W., & Tingley, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643822 · Cited by 8
“GLP1R agonists mediate their effects on food intake, body weight and metabolic processes 12–15 , by activating GLP1Rs expressed by specific cell types in the brain, pancreas and other peripheral tissues 16–19 .”
Giménez‐Palop, O., Romero, A., Casamitjana, L., Pareja, R., Rigla, M., & Caixàs, A. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.12.001 · Cited by 15
“…obesity (14) (15), making it a potentially viable option for individuals with PWS. Liraglutide specifically acts on the pro-opiomelanocortin and cocaine-amphetamine-regulated transcript (POMC/CART) neurons within the arcuate nucleus, the primary center regulating appetite in the hypothalamus (16).”
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
“A wealth of preclinical and clinical data has supported and accompanied the development of GLP-1 based therapies for type 2 diabetes and obesity (Secher et al., 2014; Gabery et al., 2020), a market now worth billions of dollars per year.”
Aguggia, J. P., Fernández, G., Cassano, D., Mustafá, E. R., Rodríguez, S., Cantel, S., Fehrentz, J., Raingo, J., Schiöth, H. B., Habib, A. M., et al. (2024) · Endocrinology · doi:10.1210/endocr/bqae160 · Cited by 6
Neuroendocrinology and the Genetics of Obesity
Ruggiero-Ruff, R. E., & Coss, D. (2025) · Endocrinology · doi:10.1210/endocr/bqaf121 · Cited by 8
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
“This was supported by the finding of radiolabeled liraglutide in the arcuate nucleus following subcutaneous liraglutide administration with higher doses than those used for T2DM treatment[84].”
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 23
A brain reward circuit inhibited by next-generation weight-loss drugs in mice
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A., Li, O., Ogilvie, S., Keeler, A. B., Tian, G., Shi, Y., Koita, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10444-4 · Cited by 23
Glucagon-like peptide-1 analogues for overweight or obese adults
Madrid, E., Vargas, M. O., Contreras, C., Saldías, C., Liquitay, C. M. E., Victoria Novik, A., Muñoz, S., & Bracchiglione, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092 · Cited by 7
Pal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 8
Genetics, pharmacotherapy, and dietary interventions in childhood obesity
Son, J. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12861 · Cited by 15
Giménez‐Palop, O., Romero, A., Casamitjana, L., Pareja, R., Rigla, M., & Caixàs, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2023.12.009 · Cited by 6
Incretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
“The GLP-1R agonist liraglutide can directly activate anorectic POMC/CART neurons in rodents and thus indirectly inhibit orexigenic AgRP/NPY neurons in the ARC to reduce food intake [74].”
BackgroundFunctional and multi-omic aging rejuvenation with GLP-1R agonismPreprint
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Zheng, X., Chow, H. T., Lo, M. P. S., Li, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592653 · Cited by 6
Shen, J., Wang, M., Pang, G., Zhang, Y., Zhang, J., Shi, Y., Liu, J., & Zhan, C. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00528.2024 · Cited by 7
Arrowaili, A. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07856-y · Cited by 7
“The activities of GLP-1 ultimately result in reduced energy intake, enhancing its beneficial effect on weight loss [67].”
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
“Moreover, liraglutide binds to proopiomelanocortin and cocaine-and amphetamine-regulated transcript (POMC/ CART)-expressing arcuate nucleus neurons, stimulating satiety-promoting pathways while inhibiting orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons [57].”
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
Salerno, E., Fumarulo, I., Garramone, B., Vaccarella, M., Ierardi, C., Burzotta, F., & Aspromonte, N. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103213 · Cited by 6
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
“Despite variable BBB permeability, the neuroprotective efficacy of different GLP-1RAs suggests that even those with limited direct brain uptake can exert central effects, possibly via circumventricular organs or indirect mechanisms (e.g., peripheral immune modulation) [7,21].”
Jiang, W., Skoug, C., Rodrigues, I., Ciabatti, E., Gribble, F. M., Reimann, F., Brierley, D. I., Holt, M. K., & Trapp, S. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102347 · Cited by 5
Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs)
Weirath, N. A., & Haskell‐Luevano, C. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00129 · Cited by 5
Pharmacotherapies for Binge Eating Disorder: Systematic Review and Network Meta‐Analysis
Costa, G. P. A., de Assunção, B. R., Belfort‐DeAguiar, R., & Nunes, J. C. (2025) · Obesity Reviews · doi:10.1111/obr.13936 · Cited by 10
“In the brain, GLP-1 RAs influence hypothalamic hunger and satiety regulation [96] and modulate appetite and binge-eating behaviors through serotonin (5-HT) pathways in the hindbrain [97].”
Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats
Cao, X., Zhou, X., Liu, X., & Zhou, L. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0001 · Cited by 5
Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia
Choi, S. A., Jee, H. J., Bormate, K. J., Kim, Y., & Jung, Y.-S. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.115 · Cited by 6
“The inhibition of neuropeptide Y and agouti-related peptides and the activation of proopiomelanocortin neurons cause reduced food intake and fullness (Secher et al ., 2014).”
BackgroundChartoumpekis, D. V., Habeos, E. E., & Psilopanagioti, A. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100104 · Cited by 6
“…of a GLP-1R agonist regulates neuronal expression of cocaine-and amphetamine-regulated transcript (CART) and neuropeptide Y (NPY)/Agouti-related protein (AgRP) (increased CART and reduced the expression of NPY, AgRP) in the arcuate nucleus and decreases food intake and body weight [14].”
BackgroundWulff, B. S., Kuhre, R. E., Selvaraj, M., Rehfeld, J. F., Niss, K., Fels, J. J., Secher, A., Raun, K., & Gerstenberg, M. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32009 · Cited by 6
Self-citationThe Emerging Role of GLP-1 Agonists in Burn Care: What Do We Know?
Manasyan, A., Cannata, B., Ross, E. E., Lasky, S., Stanton, E. W., Malkoff, N., Collier, Z. J., Johnson, M. B., & Gillenwater, J. T. (2024) · Journal of Burn Care & Research · doi:10.1093/jbcr/irae189 · Cited by 6
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Lawati, A. A., Alhabsi, A. N., Rahul, R., Savino, M.-L., Alwahaibi, H., Das, S., & Lawati, H. A. (2025) · Diseases · doi:10.3390/diseases13050129 · Cited by 6
“This central mechanism helps regulate feelings of hunger and satiety, food intake body weight, fat This central mechanism helps regulate feelings of hunger and sa-tiety, food intake, body weight, fat mass, and energy metabolism, including fa tt y acid oxidation [30].”
The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1
Chao, D. H. M., Wang, Y., Foppen, E., Ottenhoff, R., van Roomen, C. P. A. A., Parlevliet, E. T., van Eijk, M., Verhoek, M., Boot, R. G., Marques, A. R. A., et al. (2019) · Diabetes · doi:10.2337/db19-0049 · Cited by 5
Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
Manu, P., Lăcătușu, C.-M., Rogozea, L. M., & Cernea, S. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001524 · Cited by 12
Recent Advances in Anti-Obesity Drugs
Son, J. W. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.113 · Cited by 5
“리라글루타이드는 glucagon-like peptide-1 (GLP-1)수용체를 활성화시키 는 GLP-1유사체로, GLP-1과 97%의 동일성을 보이며 체내 에서 장시간 작용하는 것이 특징이다[32].”
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Murphy, C. F., & le Roux, C. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.06 · Cited by 4
Pharmacologic treatment of obesity
Jung, H. N., & Jung, C. H. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.7.408 · Cited by 5
“Liraglutide는 시상하부에서 궁상핵의 GLP1 수용체에 결합하여 식욕을 억제하는 POMC/cocaine 및 amphetamine 조절 전사 신경을 활성화하는 한편, 식욕을 높이는 neuropeptide Y/agouti-related protein 신경을 억 제한다[31].”
InfluentialObesity in women’s life: role of GLP-1 agonists
Palacios, S. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2163235 · Cited by 5
“The mechanism of action of Liraglutide is mainly in the arcuate nucleus of the hypothalamus by activating POMC/CART neurons [14], causing satiety and less appetite.”
BackgroundThe Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025) · Nutrients · doi:10.3390/nu17193038 · Cited by 4
“POMC/CART neurons that express GLP-1 receptors activate PB neurons and directly or indirectly suppress NPY/AgRP neurons [69,70], leading to disinhibition of suppressive signals to the PB.”
Gao, C., Geneve, I. C., Rodriguez-Gonzalez, S., Li, C., McElhern, K., Reitman, M. L., Lutas, A., & Krashes, M. J. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01534-8 · Cited by 10
“…of GLP1RAs induces a distributed network of neuronal activation in regions implicated in central appetite regulation, such as the parabrachial nucleus (PBN), central amygdala (CeA), area postrema (AP), nucleus of the solitary tract (NTS) and bed nucleus of the stria terminalis (BNST) 3,7–10 .”
Hammad, M. A. M., Quesada, S. G., Belczyk, A. L., & Ghoniem, G. M. (2025) · Toxins · doi:10.3390/toxins17110542 · Cited by 8
“Studies suggest that, rather than acting primarily through GLP-1-producing neurons in the hindbrain or GLP-1 receptors in the vagus nerve, these drugs mediate weight loss via the arcuate nucleus (ARC) of the hypothalamus [55,56].”
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
“Furthermore, the degree to which various exogenous GLP1-RAs penetrate the blood–brain barrier (BBB) and access central receptors remains unresolved and an ongoing area of research.”
InfluentialGLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 5
Galsgaard, K. D., Modvig, I. M., & Holst, J. J. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241062 · Cited by 4
Wretlind, A., Zobel, E. H., de Zawadzki, A., Ripa, R. S., Curovic, V. R., von Scholten, B. J., Mattila, I. M., Hansen, T. W., Kjær, A., Vestergaard, H., et al. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.856485 · Cited by 4
Zhou, M., Du, M., Tang, R., Liu, H., Gao, Z., Wang, Y., You, H., Hao, J.-W., Ji, Z., Wang, D., et al. (2023) · Neuroendocrinology · doi:10.1159/000529438 · Cited by 5
GLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats
Morais, T., Pereira, S. S., Andrade, S., Neves, D., Guimarães, M., Nora, M. C., Carreira, M. C., Casanueva, F. F., & Monteiro, M. P. (2023) · Biomedicines · doi:10.3390/biomedicines11051322 · Cited by 4
“GLP-1R activity in vagal afferent neurons were recognized to be crucial to mediate the effects of endogenous GLP-1 on food intake [38], but not necessarily for GLP-1 analogues that seem to act directly on the hypothalamic neurons [39].”
Background
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.